<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486627</url>
  </required_header>
  <id_info>
    <org_study_id>ACHN-490-009</org_study_id>
    <secondary_id>2015-001588-37</secondary_id>
    <secondary_id>U1111-1171-1554</secondary_id>
    <nct_id>NCT02486627</nct_id>
  </id_info>
  <brief_title>A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)</brief_title>
  <acronym>EPIC</acronym>
  <official_title>A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achaogen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achaogen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, multinational, double-blind study comparing the efficacy
      and safety of plazomicin compared with meropenem followed by optional oral (PO) therapy in
      the treatment of cUTI, including AP, in adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome requiring both microbiological eradication and clinical cure rate in the microbiological modified intent-to-treat population</measure>
    <time_frame>Day 5 after study drug start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite outcome requiring both microbiological eradication and clinical cure rate in the microbiological modified intent-to-treat population</measure>
    <time_frame>Day 17 (+/- 2 days) after study drug start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite outcome requiring both microbiological eradication and clinical cure rate in the microbiologically evaluable population</measure>
    <time_frame>Day 5 after study drug start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite outcome requiring both microbiological eradication and clinical cure rate in the microbiologically evaluable population</measure>
    <time_frame>Day 17 (+/- 2 days) after study drug start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of adverse events</measure>
    <time_frame>34 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">609</enrollment>
  <condition>Complicated Urinary Tract Infection</condition>
  <condition>Acute Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Plazomicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous repeating doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous repeating doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>plazomicin</intervention_name>
    <arm_group_label>Plazomicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meropenem</intervention_name>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin (oral)</intervention_name>
    <description>Oral switch after completion of study drug when clinically appropriate</description>
    <arm_group_label>Plazomicin</arm_group_label>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Pyuria

          -  Have a pretreatment baseline urine culture obtained within 36 hours before the start
             of administration of the first dose of study drug

          -  Clinical signs and/or symptoms of acute pyelonephritis or complicated urinary tract
             infection

          -  Normal renal function or moderate renal impairment

        Key Exclusion Criteria:

          -  Confirmed fungal urinary tract infection at the time of randomization

          -  Known urinary tract infection or colonization with Gram-positive pathogens

          -  Current cUTI or AP is known to be caused by a pathogen resistant to meropenem

          -  Female patients of childbearing potential if they are known to be pregnant or have a
             positive pregnancy test at screening, breastfeeding, or unable or unwilling to use a
             highly effective method of birth control during the study and for at least 30 days
             following the last dose of study medication

          -  Any rapidly progressing disease or immediately life-threatening illness

          -  Documented presence of immunodeficiency or an immunocompromised condition

          -  Documented or known history of otologic surgery or disease including use of hearing
             aid, head injury leading to otologic damage, Ménière's disease, tumor of the head,
             neck, or auditory system, perilymphatic fistula, or autoimmune disease of the inner
             ear, or family history of hearing loss (excluding age-related hearing loss [onset
             after age of 65 years])
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn E Connolly, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Achaogen, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cUTI</keyword>
  <keyword>AP</keyword>
  <keyword>ACHN-490</keyword>
  <keyword>anti-infective</keyword>
  <keyword>anti-bacterial</keyword>
  <keyword>antibiotic</keyword>
  <keyword>anti-microbial</keyword>
  <keyword>UTI</keyword>
  <keyword>bacterial infection</keyword>
  <keyword>Gram-negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

